Literature DB >> 18549781

ApoE promotes the proteolytic degradation of Abeta.

Qingguang Jiang1, C Y Daniel Lee, Shweta Mandrekar, Brandy Wilkinson, Paige Cramer, Noam Zelcer, Karen Mann, Bruce Lamb, Timothy M Willson, Jon L Collins, Jill C Richardson, Jonathan D Smith, Thomas A Comery, David Riddell, David M Holtzman, Peter Tontonoz, Gary E Landreth.   

Abstract

Apolipoprotein E is associated with age-related risk for Alzheimer's disease and plays critical roles in Abeta homeostasis. We report that ApoE plays a role in facilitating the proteolytic clearance of soluble Abeta from the brain. The endolytic degradation of Abeta peptides within microglia by neprilysin and related enzymes is dramatically enhanced by ApoE. Similarly, Abeta degradation extracellularly by insulin-degrading enzyme is facilitated by ApoE. The capacity of ApoE to promote Abeta degradation is dependent upon the ApoE isoform and its lipidation status. The enhanced expression of lipidated ApoE, through the activation of liver X receptors, stimulates Abeta degradation. Indeed, aged Tg2576 mice treated with the LXR agonist GW3965 exhibited a dramatic reduction in brain Abeta load. GW3965 treatment also reversed contextual memory deficits. These data demonstrate a mechanism through which ApoE facilitates the clearance of Abeta from the brain and suggest that LXR agonists may represent a novel therapy for AD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18549781      PMCID: PMC2493297          DOI: 10.1016/j.neuron.2008.04.010

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  68 in total

Review 1.  Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis.

Authors:  Wei Qiao Qiu; Marshal F Folstein
Journal:  Neurobiol Aging       Date:  2005-02-17       Impact factor: 4.673

2.  Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease.

Authors:  J Steven Jacobsen; Chi-Cheng Wu; Jeffrey M Redwine; Thomas A Comery; Robert Arias; Mark Bowlby; Robert Martone; John H Morrison; Menelas N Pangalos; Peter H Reinhart; Floyd E Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-20       Impact factor: 11.205

3.  The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease.

Authors:  Veronica Hirsch-Reinshagen; Luis F Maia; Braydon L Burgess; Jean-Francois Blain; Kathryn E Naus; Sean A McIsaac; Pamela F Parkinson; Jennifer Y Chan; Gavin H Tansley; Michael R Hayden; Judes Poirier; William Van Nostrand; Cheryl L Wellington
Journal:  J Biol Chem       Date:  2005-10-05       Impact factor: 5.157

Review 4.  Neurovascular pathways and Alzheimer amyloid beta-peptide.

Authors:  Berislav V Zlokovic; Rashid Deane; Jan Sallstrom; Nienwen Chow; Joseph M Miano
Journal:  Brain Pathol       Date:  2005-01       Impact factor: 6.508

Review 5.  Influence of the susceptibility genes apolipoprotein E-epsilon 4 and apolipoprotein E-epsilon 2 on the rate of disease expressivity of late-onset Alzheimer's disease.

Authors:  A D Roses; A M Saunders; E H Corder; M A Pericak-Vance; S H Han; G Einstein; C Hulette; D E Schmechel; M Holsti; D Huang
Journal:  Arzneimittelforschung       Date:  1995-03

6.  Microglial phagocytosis of fibrillar beta-amyloid through a beta1 integrin-dependent mechanism.

Authors:  Jessica Koenigsknecht; Gary Landreth
Journal:  J Neurosci       Date:  2004-11-03       Impact factor: 6.167

7.  Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death.

Authors:  Malcolm A Leissring; Wesley Farris; Alice Y Chang; Dominic M Walsh; Xining Wu; Xiaoyan Sun; Matthew P Frosch; Dennis J Selkoe
Journal:  Neuron       Date:  2003-12-18       Impact factor: 17.173

8.  Molecular and cellular physiology of apolipoprotein A-I lipidation by the ATP-binding cassette transporter A1 (ABCA1).

Authors:  Maxime Denis; Bassam Haidar; Michel Marcil; Michel Bouvier; Larbi Krimbou; Jacques Genest
Journal:  J Biol Chem       Date:  2003-12-04       Impact factor: 5.157

9.  Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides.

Authors:  Milla Koistinaho; Suizhen Lin; Xin Wu; Michail Esterman; Deanna Koger; Jeffrey Hanson; Richard Higgs; Feng Liu; Seema Malkani; Kelly R Bales; Steven M Paul
Journal:  Nat Med       Date:  2004-06-13       Impact factor: 53.440

10.  The effects of ABCA1 on cholesterol efflux and Abeta levels in vitro and in vivo.

Authors:  Mark P Burns; Lilit Vardanian; Ahdeah Pajoohesh-Ganji; Lili Wang; Matthew Cooper; Donnie C Harris; Karen Duff; G William Rebeck
Journal:  J Neurochem       Date:  2006-06-12       Impact factor: 5.372

View more
  373 in total

1.  Sensory network dysfunction, behavioral impairments, and their reversibility in an Alzheimer's β-amyloidosis mouse model.

Authors:  Daniel W Wesson; Anne H Borkowski; Gary E Landreth; Ralph A Nixon; Efrat Levy; Donald A Wilson
Journal:  J Neurosci       Date:  2011-11-02       Impact factor: 6.167

2.  Association of APOE with tau-tangle pathology with and without β-amyloid.

Authors:  Jose M Farfel; Lei Yu; Philip L De Jager; Julie A Schneider; David A Bennett
Journal:  Neurobiol Aging       Date:  2015-09-28       Impact factor: 4.673

Review 3.  HDL-cholesterol and apolipoproteins in relation to dementia.

Authors:  Manja Koch; Majken K Jensen
Journal:  Curr Opin Lipidol       Date:  2016-02       Impact factor: 4.776

4.  Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice.

Authors:  Andrew W Kraft; Xiaoyan Hu; Hyejin Yoon; Ping Yan; Qingli Xiao; Yan Wang; So Chon Gil; Jennifer Brown; Ulrika Wilhelmsson; Jessica L Restivo; John R Cirrito; David M Holtzman; Jungsu Kim; Milos Pekny; Jin-Moo Lee
Journal:  FASEB J       Date:  2012-10-04       Impact factor: 5.191

5.  Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E.

Authors:  Shanna L Burke; Peter Maramaldi; Tamara Cadet; Walter Kukull
Journal:  Int J Geriatr Psychiatry       Date:  2017-05-31       Impact factor: 3.485

6.  Epigenetic Regulation of SNAP25 Prevents Progressive Glutamate Excitotoxicty in Hypoxic CA3 Neurons.

Authors:  Suryanarayan Biswal; Debashree Das; Kalpana Barhwal; Ashish Kumar; Tapas Chandra Nag; Mahendra Kumar Thakur; Sunil Kumar Hota; Bhuvnesh Kumar
Journal:  Mol Neurobiol       Date:  2016-10-03       Impact factor: 5.590

7.  Prostaglandin signaling suppresses beneficial microglial function in Alzheimer's disease models.

Authors:  Jenny U Johansson; Nathaniel S Woodling; Qian Wang; Maharshi Panchal; Xibin Liang; Angel Trueba-Saiz; Holden D Brown; Siddhita D Mhatre; Taylor Loui; Katrin I Andreasson
Journal:  J Clin Invest       Date:  2014-12-08       Impact factor: 14.808

Review 8.  ApoE and Aβ in Alzheimer's disease: accidental encounters or partners?

Authors:  Takahisa Kanekiyo; Huaxi Xu; Guojun Bu
Journal:  Neuron       Date:  2014-02-19       Impact factor: 17.173

Review 9.  Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders.

Authors:  Vijay K Ramanan; Andrew J Saykin
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

10.  Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance.

Authors:  Jungsu Kim; Joseph M Castellano; Hong Jiang; Jacob M Basak; Maia Parsadanian; Vi Pham; Stephanie M Mason; Steven M Paul; David M Holtzman
Journal:  Neuron       Date:  2009-12-10       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.